FOLH1 and pachyonychia congenita: Although PSMA PET/CT has been previously used in tandem with other systemic treatments to evaluate the response and predict OS in patients with metastatic PC, the effects of BAT as a novel systemic treatment on PSMA expression remain relatively unexplored.